PMC10148232_01
Concentric visual field restrictions on a 30-2 Humphrey field analyser in (a) right eye and (b) left eye at presentation, with mean deviation of -10.08 dB (OD) and -16.46 dB (OS). The visual threshold greyscale map, numerical sensitivity plot, total deviation, and pattern deviation for each eye are shown from left to right.
cop530221_f01.jpg
PMC10148232_01_cop530221_f01.jpg
F1
Repeatable concentric visual field constriction was confirmed in both eyes on 30-2 Humphrey visual field testing at presentation (shown in Fig. 1a, b) and at 3 months' follow-up (shown in Fig. 2a, b).
Significant improvement of visual fields on a 30-2 Humphrey field analyser in (a) right eye and (b) left eye 3 months after discontinuation of therapy, with a mean deviation of -1.98 dB (OD) and -1.60 dB (OS). The visual threshold greyscale map, numerical sensitivity plot, total deviation, and pattern deviation for each eye are shown from left to right.
cop530221_f03.jpg
PMC10148232_01_cop530221_f03.jpg
F3
Three months after discontinuation of ezetimibe, there was near complete resolution of the bilateral concentric field loss and significant symptom improvements (shown in Fig. 3a, b).
Complete resolution of visual field deficits on a 30-2 Humphrey field analyser in (a) right eye and (b) left eye 12 months after discontinuation of therapy, with a mean deviation of +1.25 dB (OD) and +0.25 dB (OS). The visual threshold greyscale map, numerical sensitivity plot, total deviation, and pattern deviation for each eye are shown from left to right.
cop530221_f04.jpg
PMC10148232_01_cop530221_f04.jpg
F4
Twelve months after therapy discontinuation, visual fields returned to baseline in both eyes, and there were no new symptoms (shown in Fig. 4a, b).